GLMD

Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. (GLMD) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (A); its weakest is Profitability (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B
Factor Score 3.2 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
A
Factor Score 4.4 / 5.0
Revisions
C-
Factor Score 2.1 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.5
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 506.0%
Price Return 12M 86.9%
Catalyst Signal 0.00
Market Cap $4.9M
TTM Revenue N/A
Price / Sales N/A
ROE -68.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-09-17 B (3.2) C+ (2.5) C- (1.9) A (4.4) C- (2.1) C+ (2.8)
2026-09-10 B- (3.1) C+ (2.5) C- (2.0) C- (2.0) C- (1.9) C (2.3)
2026-09-03 B- (3.1) C+ (2.5) C- (2.0) A+ (4.9) C+ (2.5) B- (3.0)
2026-08-27 B- (3.0) C (2.4) B- (2.9) A+ (4.9) C (2.3) B- (3.1)
2026-08-20 B- (3.0) C (2.4) B- (2.9) C- (2.0) C (2.4) C+ (2.5)
Page 1 of 3